Information 2024 Life Science Intellectual Property Forum Now is the time to strengthen Japan's drug discovery capabilities! ～Toward Building a Robust Drug Discovery Ecosystem for New Modalities
The "2024 Life Science IP Forum" will be held on Wednesday, February 7, 2024 at 1:00 p.m. at Ochanomizu Sola City Conference Center (Chiyoda-ku, Tokyo).
Outline of Implementation
| Date and Time | Wednesday, February 7, 2024, 13:00-17:00 |
|---|---|
| Venue | Ochanomizu Sola City Conference Center 4-6 Kanda-Surugadai, Chiyoda-ku, Tokyo *Webcasting will be conducted from the venue, but no questions will be answered. No Q&A will be available. No archived streaming is planned. |
| Participation Fee | There is no charge for this event. |
At the "2023 Life Science IP Forum," participants discussed the challenges and prospects for the social implementation of digital therapeutics (DTx), highlighting dramatic changes in the business environment, including the need for a new business model involving many players, including those from different industries, and speedy collaboration. The discussion highlighted the dramatic changes in the business environment.
The "Intellectual Property Promotion Plan 2023," released by the Cabinet Office in June 2023, states that open innovation (OI) is indispensable for sustainable value creation in companies, that in promoting OI, the startup and university IP ecosystems must be strengthened, and that a variety of players must participate to create new added value. The importance of forming an ecosystem in which diverse players can participate to create new value-added products and implement them in society, etc. is also indicated.
In the pharmaceutical industry, Hiroaki Ueno, Chairman of the Pharmaceutical Manufacturers Association of Japan (PMAJ), in a press conference held on May 25, 2023, expressed his belief that a shift to a "drug discovery ecosystem" in which multiple players collaborate, rather than individual companies completing their work, is important to "strengthen Japan's drug discovery capabilities" and that this can be achieved through four important points (1) The four key points are (1) practical application of basic drug discovery technologies, (2) sustainable start-up and nurturing of start-ups, (3) enhancement of new modality manufacturing capabilities, and (4) development of a foundation for data utilization. The company has stated that it will work on four points while considering the "missing piece" to create a virtuous cycle in the drug discovery ecosystem.
New-modality drug discovery (e.g., cell therapy drugs, gene therapy drugs, etc.) differs from the conventional small molecule drug discovery business model, and academia and start-ups will play an increasingly important role. In addition, it is important to build win-win relationships with various players, including equipment and device manufacturers, contract manufacturing and development organizations, and others. It is important to distribute profits according to the roles and contributions of each player while looking at the business as a whole, but in practice, it is said that it is difficult to build a competitive overall picture because it takes time to build relationships among individual players.
It is important to build a relationship that all players can agree on and trust, while looking at the development and business environment from a bird's eye view. Therefore, the issues of financing during the long-term development stage and the issues of profit distribution to early contributors during the commercialization stage are also important perspectives that must not be forgotten.
In this forum, we plan to discuss how to create new value in the drug discovery of new modalities by bringing together a wide variety of players to collaborate and create intellectual assets in order to create a virtuous circle in the drug discovery ecosystem. The panelists will discuss what the "missing piece" is that will strengthen cooperation among the players, what rules and regulations should be applied to the "intellectual capital" that each player brings to the table, and how roles should best be allocated. We would like to discuss with you through the speakers' speeches and panel discussions, and make recommendations on how best to share the roles of "intellectual capital" brought by each player based on rules and regulations.
Program (titles omitted)
Lecture
Progress and future prospects of CAR-T cell therapy for cancer
President, Noil Immune Biotech, Inc.
Professor, Graduate School of Medicine, Yamaguchi University Koji Tamada
Development of Japan's biotechnology policy
( Assistant Director, Biological and Chemical Industry Division, Commerce and Service Group, Ministry of Economy, Trade and Industry)
Formation of University IP Innovation Ecosystem and Challenges - Perspectives from Academia
Director, Intellectual Property Contracts and Management, Industry-Academia Collaboration Division, The University of Tokyo
Mieko Mio, Attorney at Law, Kioicho Law Offices
IP Strategies in Corporate Alliances - For Building Business Ecosystems and Realizing Open Innovation
Representative Director and CEO, Cyclo-Hygeia Co.
Makoto Kobayashi, Specially Appointed Professor, Open Innovation Organization, Osaka University
Importance of the Drug Discovery Ecosystem in the Pharmaceutical Industry and Key Factors for Creating a Virtuous Circle
Chairman, Intellectual Property Committee, Japan Pharmaceutical Manufacturers Association
Takeda Pharmaceutical Company Limited Hiroya Okumura
Panel Discussion
Moderator〉 Hiroya Okumura
Panelists〉 Koji Tamada, Takeya Sho, Mieko Mio, Makoto Kobayashi
Speakers, panelists and contents are subject to change.
［For inquiries, please contact]
Secretariat of the Preparatory Committee for the 2024 Life Science IP Forum
(Intellectual Property Committee, Japan Pharmaceutical Manufacturers Association, Attn: Yokota/Fujii)
Tel: 03-3241-0335 Fax: 03-3242-1767 E-mail: chizai-forum2024@jpma.or.jp